# Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

> **NCT05902520** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AgonOx, Inc.** · enrollment: 18 (estimated)

## Conditions studied

- HNSCC
- Melanoma
- Gynecologic Cancer
- Colorectal Cancer
- Lung Cancer
- Urogenital Cancer

## Interventions

- **BIOLOGICAL:** DP CD8 TIL
- **BIOLOGICAL:** DP CD8 TIL KD
- **BIOLOGICAL:** Low dose IL-2

## Key facts

- **NCT ID:** NCT05902520
- **Lead sponsor:** AgonOx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-19
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05902520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05902520, "Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05902520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*